Respivert Limited

Topivert Pharma Limited

Catherine Elisabeth Charron

Stuart Thomas Onions

John King-Underwood

Kazuhiro Ito

Peter John Murray

Jonathan Gareth Williams

Peter Strong

Alistair Ian Longshaw

William Garth Rapeport

Alex Herman Copmans

David Michel Adrien Taddei

Simon Christopher Hirst

Rudy Broeckx

Walter Filliers

Stephen Thom

Matthew Colin Thor Fyfe

Euan Alexander Fraser Fordyce

Garth Rapeport

Lorna Duffy

Kevin Joly

Daniel Hamza

Ito Kazuhiro

Claire Anne Marie Cariou

Hayley Tegan Angela Watson

David Michael Adrien Taddei

Keith Ray

Stephen Malcolm Thom

Alex Copmans

Scott Crowe

Robert Fenton

There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as P38 MAP knase inhibitors

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD.

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-i-yl) ureas as P38 mapkinase inhibitors

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-I-yl) ureas as P38 mapkinase inhibitors

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors

There is provided inter alia a compound of formula (I): wherein R, J, Ar, L, X, Rand Rare as defined in the specification, for use in the treatment of inflammatory disorders.

P38 MAP kinase inhibitors

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as P38 MAP knase inhibitors

There are provided compounds of formula I, 

Pyrazolyl-ureas as kinase inhibitors

There are provided compounds of formula (I) which are inhibitors of the family of p38 mitogen-activated protein kinase enzymes, and to their use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD. 

1-pyrazolyl-3-((4-((2-anilinopyrimidin-4-yl) oxy) napththalen-1-yl) ureas as p38 MAP kinase inhibitors

Pyrazole derivatives as p38 MAP inhibitors

The present invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, including all stereoisomers and tautomers, which is an inhibitor of p38 mitogen-activated protein kinase enzymes (referred to herein as p38 MAP kinase inhibitors), particularly the alpha and gamma kinase sub-types thereof, and its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as COPD.

P38MAP kinase inhibitors

There is provided a compound of formula (I) which is an inhibitor of the family of p38 mitogen-activated protein kinase enzymes, and to its use in therapy, including in pharmaceutical combinations, especially in the treatment of inflammatory diseases, including inflammatory diseases of the lung, such as asthma and COPD. 

1-pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl) ureas as p38 MAP kinase inhibitors

There are provided inter alia compounds of formula (I) wherein R, Ar, L, X, Rand Q are as defined in the specification for use in therapy, especially in the treatment of inflammatory diseases.

Growing community of inventors

London, United Kingdom

Catherine Elisabeth Charron